Tricyclo Ring System Having The Seven-membered Hetero Ring A One Of The Cyclos Patents (Class 514/217)
-
Publication number: 20100184707Abstract: The use of a substance selected from the group consisting of taurine, a taurine precursor, a taurine metabolite, a taurine derivative, a taurine analog and a substance required for the taurine biosynthesis, for manufacturing a pharmaceutical composition for preventing or inhibiting the undesirable side-effects caused to a human or an animal organism by an active ingredient that induces a high level of extracellular GABA or increases GABA receptor activation.Type: ApplicationFiled: July 4, 2008Publication date: July 22, 2010Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale)Inventors: Serge Picaud, Jose Alain Sahel, Jammoul Firas, Caroline Coriat, Manuel Simonutti
-
Publication number: 20100184744Abstract: The present invention relates to a method of preparing a pharmaceutical co-crystal composition, said method comprising the steps of: a. simultaneously contacting a supercritical or liquefied gas with solid particles of a pharmaceutically active component and with solid particles of a co-builder to form a co-crystallisation medium containing dissolved pharmaceutically active component and dissolved co-builder as well as solid particles of the pharmaceutically active component and solid particles of the co-builder; b. transforming the solid particles of the pharmaceutically active component and the solid particles of the co-builder into co-crystals of said pharmaceutically active component and said co-builder by keeping the supercritical or liquefied gas in a supercritical or liquid state until at least 80 wt. % of the pharmaceutically active component is incorporated in the crystal matrix of said co-crystals; and c.Type: ApplicationFiled: July 17, 2008Publication date: July 22, 2010Inventors: Gerda Maria Van Rosmalen, Gerard Willem Hofland
-
Publication number: 20100178331Abstract: Disclosed is a preparation for transnasal application, which has improved fluidability. Specifically disclosed is a preparation for transnasal application, which comprises at least a complex comprising: a fluidability-improving component comprising a first crystalline cellulose (A) having specified powder properties, tricalcium phosphate (B) having specified powder properties, and a second crystalline cellulose (C) having specified powder properties or a starch (D) having specified powder properties; and a physiologically active substance.Type: ApplicationFiled: December 25, 2007Publication date: July 15, 2010Inventors: Ryoichi Nagata, Shunji Haruta
-
Publication number: 20100173893Abstract: A process for preparing a compound of the formula IA or IB: wherein R is alkyl, aminoalkyl, halogenalkyl, aralkyl, cycloalkyl, cycloalkylalkyl, alkoxy, phenyl or substituted phenyl or pyridyl group; the term alkyl means carbon chain, straight or branched, containing from 1 to 18 carbon atoms; the term halogen represents fluorine, chlorine, bromine or iodine; the term cycloalkyl represents a saturated alicyclic group with 3 to 6 carbon atoms; the term aryl represents unsubstituted phenyl group or phenyl substituted by alkoxy, halogen or nitro group, the process comprising asymmetric hydrogenation of a compound of the formula II: wherein R has the same meanings as above, using a chiral catalyst and a source of hydrogen.Type: ApplicationFiled: April 11, 2007Publication date: July 8, 2010Inventors: Bing Yu, Wenge Li, David Alexander Learmont
-
Publication number: 20100166860Abstract: A method and a medicine for treating a human having a gastrointestinal disorder that includes acquired lactose-intolerance irritable bowel syndrome are provided. The method includes administering a dose of the medicine to the human. The medicine includes ducosate sodium, tolterodine salt and imipramine salt.Type: ApplicationFiled: March 4, 2010Publication date: July 1, 2010Inventor: James E. Lundeen, SR.
-
Publication number: 20100166889Abstract: The invention provides methods of treating depressive disorders, in particular major depression but other depressive orders also, with prodrug stimulants or analogs including amphetamine prodrugs, methylphenidate prodrugs, and methylphenidate analogs, Such methods of treatment may utilize the prodrug stimulant or analog as monotherapy or, more commonly, as an adjunct to antidepressant medication treatment to augment their effect. The invention includes combination methods of treatment in which an amphetamine prodrug, methylphenidate prodrug, or methylphenidate analog is administered to an individual in need with one or more other active agents, either in separate forms or as a single pharmaceutical formulation. Packaged pharmaceutical compositions containing an amphetamine or methylphenidate prodrug, instructions for using the prodrug to treat certain disorders, and optionally one or more other active agents are provided by the invention.Type: ApplicationFiled: December 23, 2009Publication date: July 1, 2010Applicant: LCS GROUP, LLCInventor: Louis Sanfilippo
-
Patent number: 7745426Abstract: The present invention relates to compounds and compositions useful for reducing the risk of epileptic occurrences and/or for alleviating epileptic phenomena in patients. In accordance with the invention, the compounds and compositions have at least the following two components: a) vitamin B6-based component selected from pyridoxal, pyridoxamine, pyridoxine, their pharmaceutically acceptable functional derivatives and salts; and b) at least one antiepileptic drug (AED) or anticonvulsive, neuro-protective drug or nootrope compound or moiety. The invention further relates to methods for preventing epileptic episodes and for alleviating epileptic episodes, as well as methods for reducing side effects of antiepileptic drugs.Type: GrantFiled: August 12, 2004Date of Patent: June 29, 2010Assignees: D-Pharm Ltd., Advanced Neuroprotective Systems Ltd.Inventors: Svetlana Dolina, Vitaly Shteiman, Marina Vinnikova, Israel Shapiro
-
Publication number: 20100159034Abstract: The present invention relates to new pyrrolidinone inhibitors of PDE-4 activity, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: December 15, 2009Publication date: June 24, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Thomas G. Gant, Sepehr Sarshar
-
Publication number: 20100160295Abstract: Methods of preventing and/or treating at least one symptom of Restless Leg Syndrome (RLS) and its related disorders, including disorders such as periodic limb movements in sleep (PLMS) and periodic limb movement disorder (PLMD), are disclosed. The methods comprise identifying a host, afflicted with Restless Leg Syndrome (RLS) and its related disorders; and administering to the host a pharmaceutically effective amount of a 4-hydroxyphenylpyruvate dioxygenase. Also provided are methods and compositions for treating/preventing sleep disorders, and methods and compositions for improving sleep quantity and adequacy.Type: ApplicationFiled: November 6, 2009Publication date: June 24, 2010Applicant: SYNOSIA THERAPEUTICSInventors: Lesley PICKFORD, Uwe Meya, Mark Moran
-
Publication number: 20100159033Abstract: The present invention relates to new benzisoxazole modulators of D2 receptors and/or 5-HT2A receptors, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: September 25, 2009Publication date: June 24, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Thomas G. Gant, Manoucherhr M. Shahbaz
-
Publication number: 20100159000Abstract: A method and a medicine for treating a human having a gastrointestinal disorder that includes fecal incontinence and/or urgency are provided. The method includes administering a dose of the medicine to the human. The medicine includes capsaicin (including one or more of: capsaicin, dihydrocapsaicin, nordihydrocapsaicin, homodihydrocapsaicin and homocapsaicin), a salt of imipramine and ducosate sodium.Type: ApplicationFiled: March 1, 2010Publication date: June 24, 2010Inventor: James E. Lundeen, SR.
-
Publication number: 20100160296Abstract: Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are triphenyl methane analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, inflammatory, degenerative and vascular diseases, and parasitic infections. The compounds are triphenyl methane analogs of imipramine blue and analogs thereof, as defined herein. The compounds are believed to function by inhibiting tNOX expression, the effects of ROS, and/or the production of HIF2. Thus, the compounds are novel therapeutic agents for a variety of cancers and other diseases.Type: ApplicationFiled: December 21, 2009Publication date: June 24, 2010Applicant: EMORY UNIVERSITYInventor: Jack L. Arbiser
-
Publication number: 20100143462Abstract: The present invention relates to pharmaceutical compositions in the form of microcmulsions comprising carbamazcpinc and their enhanced permeability and extended release properties. The microcmulsion composition may be an oil based formulation or a oil/aqueous phase mixed formulation.Type: ApplicationFiled: December 6, 2005Publication date: June 10, 2010Applicant: NUTRALEASE LTD.Inventors: Nissim Garti, Abraham Aserin, Anna Kogan
-
Patent number: 7718649Abstract: An amorphous form of imipramine pamoate, morphologically pure forms, and mixtures of amorphous and morphologically pure imipramine pamoate characterized by differential scanning calorimetry, fourier transform infrared, and powder x-ray diffraction, and pharmaceutical compositions formed therefrom.Type: GrantFiled: November 10, 2006Date of Patent: May 18, 2010Assignee: Pisgah Labs, Inc.Inventors: Clifford Riley King, David William Bristol, Vicki Haynes Audia, Joseph Pike Mitchener, Jr.
-
Publication number: 20100120745Abstract: The present disclosure relates generally to treating or preventing diseases associated with angiogenesis by administering to a patient certain compounds found to inhibit or substantially reduce angiogenesis. Compounds employed according to the present disclosure exhibit good anti-angiogenic activity as well as demonstrate a prophylactic effect for preventing and substantially reducing angiogenesis. Examples of such compounds include Ritanserin, Amiodarone, Terfenadine, Perphenazine, Bithionol, and Clomipramine.Type: ApplicationFiled: October 9, 2009Publication date: May 13, 2010Applicant: Southern Research InstituteInventors: Zhican Qu, Anshu M. Roy, Subramaniam Ananthan
-
Publication number: 20100120746Abstract: The present invention relates to the use of a mixture of the enantiomers of a compound of formula I or of pharmaceutically acceptable salts of said enantiomers consisting of at least 55% of the R-enantiomer, most preferably of at least 98% of the R-enantiomer, and not more than 45% of the S-enantiomer, most preferably not more than 2% of the S-enantiomer, for the manufacture of a pharmaceutical composition for the treatment of neuropathic pain; to a method for the treatment of neuropathic pain; and to a pharmaceutical composition comprising as active agent a mixture of the enantiomers of the compound of formula I or pharmaceutically acceptable salts of said enantiomers consisting of at least 55% of the R-enantiomer and not more than 45% of the S-enantiomer.Type: ApplicationFiled: December 8, 2009Publication date: May 13, 2010Inventors: Alyson Fox, Stuart Bevan
-
Publication number: 20100120744Abstract: The present invention relates to new acetamidopropane modulators of NMDA receptor, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: September 18, 2009Publication date: May 13, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventor: Thomas G. Gant
-
Publication number: 20100119624Abstract: The present invention relates to new benzisoxazole modulators of D2 receptors and/or 5-HT2A receptors, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: September 17, 2009Publication date: May 13, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Thomas G. Gant, Sepehr Sarshar
-
Publication number: 20100119622Abstract: The present invention relates to new 3H-benzooxazol-2-one modulators of D2 receptors and/or 5-HT1A receptors, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: September 15, 2009Publication date: May 13, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Thomas G. Gant, Sepehr Sarshar
-
Patent number: 7713959Abstract: Disclosed are pharmaceutical compositions comprising mirtazapine and an anticonvulsant drug. Also disclosed are methods of preventing weight gain associated with the administration of mirtazapine comprising identifying a patient to whom mirtazapine is to be administered and administering to said patient a pharmaceutical composition comprising mirtazapine and an anticonvulsant drug. Further disclosed are methods of increasing the efficacy of mirtazapine comprising identifying a patient to whom mirtazapine is to be administered and administering to said patient a pharmaceutical composition comprising mirtazapine and an anticonvulsant drug.Type: GrantFiled: August 31, 2005Date of Patent: May 11, 2010Assignee: Duke UniversityInventors: K. Ranga R. Krishnan, Kishore M. Gadde
-
Pharmaceutical composition containing gabapentin or pregabalin and N-type calcium channel antagonist
Patent number: 7713957Abstract: The present invention relates to a pharmaceutical composition useful for preventing/treating pain, which comprises combination of gabapentin or pregabalin, or pharmaceutically acceptable salts thereof and N-type calcium channel antagonists or pharmaceutically acceptable salts thereof such as a compound having the following structure.Type: GrantFiled: August 5, 2004Date of Patent: May 11, 2010Assignee: Ajinomoto Co., Inc.Inventors: Satoshi Iwayama, Hajime Koganei, Shinichi Fujita, Tomoko Takeda, Hiroshi Yamamoto, Seiji Niwa -
Patent number: 7713960Abstract: The invention disclosed herein provides for methods of treating cancer using inhibitors of the Raf/Mek/P-Erk 1/2 pathway. These inhibitors include B2AR agonists (such as ARA-211 (pirbuterol) and isoproterenol), adenylyl cyclase activators, cAMP analogs and Epac activators. The invention also provides methods for diagnosing cancer in an individual.Type: GrantFiled: July 21, 2006Date of Patent: May 11, 2010Assignee: University of South FloridaInventor: Said M. Sebti
-
Publication number: 20100104643Abstract: The present invention provides an orally deliverable pharmaceutical composition for the once-daily (OD) administration of trimipramine. The composition comprises a therapeutically effective amount of trimipramine and at least one pharmaceutically acceptable excipient. The compositions of the invention may exhibit one or more of the release profiles defined in this specification.Type: ApplicationFiled: April 14, 2008Publication date: April 29, 2010Applicant: ZYSIS LIMITEDInventors: Ian Wilding, Russell Pendleton
-
Patent number: 7704992Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.Type: GrantFiled: January 23, 2009Date of Patent: April 27, 2010Assignee: Bristol-Myers Squibb CompanyInventors: Carol Bachand, Makonen Belema, Daniel H. Deon, Andrew C. Good, Jason Goodrich, Clint A. James, Rico Lavoie, Omar D. Lopez, Alain Martel, Nicholas A. Meanwell, Van N. Nguyen, Jeffrey Lee Romine, Edward H. Ruediger, Lawrence B. Snyder, Denis R. St. Laurent, Fukang Yang, David R. Langley, Gan Wang, Lawrence G. Hamann
-
Publication number: 20100099639Abstract: The present invention provides a W/O/W multiple emulsion composition composed of an internal aqueous phase, an oil phase, and an external aqueous phase, the internal aqueous phase containing an ionic physiologically active substance and a physiologically acceptable compound having a molecular weight of 1,000 or less and generating a polyvalent counterion with two or more valencies for the ionic physiologically active substance. The W/O/W emulsion composition of the present invention not only can stably encapsulate a useful substance in its internal aqueous phase at a high encapsulation ratio, but also has high safety.Type: ApplicationFiled: October 26, 2007Publication date: April 22, 2010Applicant: CONTROLLED LIPO TECHS, INC.Inventors: Toshimitsu Terao, Takashi Imagawa, Hironobu Yanagie, Masazumi Eriguchi
-
Publication number: 20100092454Abstract: What is described is a use of an antidepressant compound, preferably belonging to the class of selective serotonin reuptake inhibitors (SSRI), for regenerating the integumentary system and/or for stimulating the growth, the original trophism and/or original pigmentation of the corresponding cutaneous appendages, particularly body hair and/or head hair, in mammals. For this purpose, the antidepressant can be formulated in a cosmetic preparation, a pharmaceutical composition, a medical device, or in the form of a culture medium, alone or in combination with a further active ingredient such as a proteolytic enzyme and/or a vitamin.Type: ApplicationFiled: December 20, 2007Publication date: April 15, 2010Inventors: Enrico De Vivo, Antonio Ponzetto, Chiara Cesano, Luisa Gennero, Gianfranco Merizzi, Emanuella Morra
-
Publication number: 20100093611Abstract: Methods of treating, ameliorating, preventing, or reducing the risk of developing an auto-immune disease and/or an inflammatory condition, such as systemic lupus erythematosus, in a patient, such as a human being, using a therapeutically effective amount of an agent(s) that inhibits the activity of one or more of histone deacetylase (HDAC), IKB kinase (IKK-2), nuclear factor kB (NF-kB), ubiquitin/proteasome and Janus kinase (JAK) are disclosed. Compounds useful in such methods are also presented.Type: ApplicationFiled: May 16, 2008Publication date: April 15, 2010Inventors: Stephen K. Horrigan, Qin Zong, Daniel Soppet, Juana Castaneda, Bo Chen, Ricardo Cibotti, Laurent P. Audoly, Anthony Coyle, Peter Kiener
-
Publication number: 20100092568Abstract: Provided are microparticles of active pharmaceutical ingredients, drug delivery vehicles comprising same, and methods for making them.Type: ApplicationFiled: December 10, 2009Publication date: April 15, 2010Inventors: E. Itzhak Lerner, Vered Rosenberger, Moshe Flashner-Barak, Anna Drabkin, Naomi Moldavski
-
Publication number: 20100087422Abstract: A method is described for treating attention deficit hyperactivity disorder (ADHD), by administering to the individual an anti-epileptic mood stabiliser at a dose which is sub-therapeutic for mood stabilisation, optionally in combination with a psychostimulant. Also described is a method of improving reading comprehension and/or fluency in an individual suffering from learning difficulties which method comprises administering to the individual an anti-epileptic mood stabiliser.Type: ApplicationFiled: February 7, 2008Publication date: April 8, 2010Applicant: GOSFORTH CENTRE (HOLDINGS) PTY LTDInventor: Philip Bird
-
Patent number: 7691847Abstract: The present invention provides methods for treating neurological diseases and disorders. Compounds that replace or enhance the function of SMN or alleviate or reduce a phenotype of cells with low SMN protein levels are provided. Screening methods and kits for identifying such compounds also are provided.Type: GrantFiled: October 17, 2003Date of Patent: April 6, 2010Assignee: The Trustees of the University of PennsylvaniaInventors: Gideon Dreyfuss, Jin Wang
-
Publication number: 20100069341Abstract: This invention is directed to a tetrahydro-pyranopyrazole cannabinoid modulator compound of formula (I): and a method for use in treating, ameliorating or preventing a cannabinoid receptor mediated syndrome, disorder or disease.Type: ApplicationFiled: November 19, 2009Publication date: March 18, 2010Inventors: Fina Liotta, Huajun Lu, Michael P. Wachter, Mingde Xia
-
Publication number: 20100063029Abstract: The present invention relates to the use of a racemate of the compound of formula (I) consisting of at least 85% S-enantiomer and not more than 15% R-enantiomer or of pharmaceutically acceptable salts of said racemate or of the S-enantiomer of formula I or of pharmaceutically acceptable salts of said anantiomer for the treatment of anxiety or other psychiatric disorders with underlying anxiety symptomatologies or for the treatment of affective and attention disorders; pharmaceutical compositions for that purpose and packages comprising said pharmaceutical compositions together with instructions for the use of said compositions for the treatment of anxiety or other psychiatric disorders with underlying anxiety symptomatologies or of affective and attention disorders.Type: ApplicationFiled: November 11, 2009Publication date: March 11, 2010Inventors: Graeme Bilbe, John F. Cryan, Conrad Gentsch, Kevin Hall Mcallister, Markus Schmutz, Annick Vassout
-
Publication number: 20100048538Abstract: New applications of eslicarbazepine and eslicarbazepine acetate in the treatment of intractable conditions, selected from epilepsy, central and peripheric nervous system disorders, affective disorders, schizoaffective disorders, bipolar disorders, attention disorders, anxiety disorders, neurophatic pain and neuropathic pain-related disorders, sensorimotor disorders, vestibular disorders, and nervous function alterations in degenerative and post-ischemic diseases. Preferably the intractable condition is, at least in part, caused by an overexpression of P-gp or MRP.Type: ApplicationFiled: January 14, 2008Publication date: February 25, 2010Applicant: BIAL - Portela & Ca S.A.Inventor: Patricio Manuel Vieira Araújo Soares Da Silva
-
Publication number: 20100035859Abstract: A method of treatment for the prevention or therapy of a protein aggregation disease includes the administration in combination of a first active medicament and a second active medicament, wherein the first active medicament is active to impede aggregation of amyloid protein and the second active medicament is active to disaggregate previously formed aggregates of amyloid protein.Type: ApplicationFiled: January 30, 2008Publication date: February 11, 2010Applicant: PAD Pharma LimitedInventors: Stuart Mark Wilson, Christopher John Stanley
-
Publication number: 20100035860Abstract: The invention relates to the use of protein tyrosine phosphatase inhibitors for the promotion of physiological cardiac hypertrophy and the treatment of pathological cardiac hypertrophy.Type: ApplicationFiled: November 30, 2007Publication date: February 11, 2010Inventors: Jey Raju Jeyaseelan, Mie Abe
-
Publication number: 20100029618Abstract: Disclosed herein is a pharmaceutical composition comprising a pain-relieving anticonvulsant and an pan-alpha-2 adrenergic receptor agonist. The composition is effective for treating chronic pain, and methods of treating chronic pain using the composition and the compounds comprising it are also disclosed.Type: ApplicationFiled: December 14, 2007Publication date: February 4, 2010Inventors: Daniel W. Gil, John E. Donello
-
Patent number: 7645750Abstract: A method for treating or preventing symptoms of hormonal variation includes administering an effective amount of a receptor antagonist to a subject having one or more symptoms of hormonal variations, wherein the receptor antagonist binds to at least one selected from the group consisting of a serotonin type 2A (5-HT2A) and a dopamine type 2 (D2) receptors.Type: GrantFiled: December 13, 2006Date of Patent: January 12, 2010Assignee: Yung Shin Pharmaceutical Ind. Co., Ltd.Inventor: Hung-Ming Wu
-
Publication number: 20090326607Abstract: An electrical stimulation method for the treatment of peripheral neuropathy is disclosed. In a preferred embodiment, the method utilizes an electrical stimulation device that includes a plurality of channels of electrodes each of which includes a first and second electrode positioned in electrical contact with tissue of a target region suffering from peripheral neuropathy. Agonist/antagonist muscles involved in abduction/adduction, flexion/extension, supination/pronation, protraction/retraction, and/or eversion/inversion in the peripheral body regions are stimulated with a patterned series of electrical pulses through channels of electrodes in accordance with a procedure for treating peripheral neuropathy.Type: ApplicationFiled: June 30, 2008Publication date: December 31, 2009Inventors: J. Chris Castel, Francis X. Palermo
-
Patent number: 7638510Abstract: The present invention relates to the use of a racemate of the compound of formula (1) consisting of at least 85% S-enantiomer and not more than 15% R-enantiomer or of pharmaceutically acceptable salts of said racemate or of the S-enantiomer of formula I or of pharmaceutically acceptable salts of said enantiomer for the treatment of anxiety or other psychiatric disorders with underlying anxiety symptomatologies or for the treatment of affective and attention disorders; pharmaceutical compositions for that purpose and packages comprising said pharmaceutical compositions together with instructions for the use of said compositions for the treatment of anxiety or other psychiatric disorders with underlying anxiety symptomatologies or of affective and attention disorders.Type: GrantFiled: February 16, 2004Date of Patent: December 29, 2009Assignee: Novartis AGInventors: Graeme Bilbe, John F. Cryan, Conrad Gentsch, Kevin Hall McAllister, Markus Schmutz, Annick Vassout
-
Publication number: 20090311325Abstract: The present invention relates generally to use of a polyvinyl alcohol-polyethylene glycol graft copolymer (PVA-PEG graft co-polymer), such as Kollicoat IR, in the formulation of solid dispersions of low aqueous solubility and dissolution rate bioactive compound and, more particularly to a system and method for improving the solubility and dissolution rate of such low aqueous solubility and dissolution rate bioactive compound, in particular the drug of low aqueous solubility, such as a BCS Class II or Class IV drug compounds.Type: ApplicationFiled: April 10, 2007Publication date: December 17, 2009Applicant: K.U.LEUVEN RESEARCH AND DEVELOPMENTInventors: Sandrien Janssens, Guy Van Den Mooter
-
Publication number: 20090306050Abstract: In accordance with the present invention, it has been discovered that compounds exhibiting activity as a potent noradrenaline reuptake inhibitor (e.g., a NA: 5HT ratio of greater than or equal to about 1000:1), and activity at the dopamine D2 receptor sites (e.g., lofepramine) are effective in the treatment and prevention of various diseases and disorders associated with noradrenaline reuptake, such as pain predominant-type depression, depression secondary to chronic or neuropathic pain, and neuropathic pain itself.Type: ApplicationFiled: February 1, 2007Publication date: December 10, 2009Inventor: Timothy Dinan
-
Publication number: 20090306051Abstract: The present invention relates to methods and compositions for treating CNS-related disorders.Type: ApplicationFiled: December 11, 2008Publication date: December 10, 2009Inventors: Laurence R. Meyerson, Gregory T. Went, Timothy J. Fultz
-
Publication number: 20090304615Abstract: A method of identification of tricyclic compounds (formula I) that control melanin synthesis (melanogenesis), and the use of such compounds and compositions thereof to modify (e.g., inhibit) melanin production are disclosed. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of conditions that are causally related to aberrant melanogenesis activity including by way of non-limiting example, hyperpigmentation and others.Type: ApplicationFiled: April 30, 2009Publication date: December 10, 2009Inventors: Seth J. ORLOW, Li Ni KOMATSU
-
Publication number: 20090306049Abstract: The invention relates to the field of biochemistry and medicine. More specifically, the invention relates to the treatment of epithelial changes in the esophagus. Even more specific, the invention relates to the treatment of Barrett's esophagus. The invention provides a method for at least in part decreasing Barrett's esophagus present in an animal comprising at least in part inhibiting Notch pathway activation in said animal. Preferably, said inhibition of Notch pathway activation is accomplished via a g-secretase inhibitor.Type: ApplicationFiled: December 8, 2006Publication date: December 10, 2009Applicant: HUBRECHT LABORATORIUMInventors: Johannes Carolus Clevers, Johannes Hendrikus van Es
-
Publication number: 20090297619Abstract: Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the agent following administration. The novel compositions release the agent following administration for a time period ranging from about 2 to about 24 hours or longer.Type: ApplicationFiled: June 11, 2009Publication date: December 3, 2009Inventors: Jon Swanson, Rajeev A. Jain, Robert Hontz, John G. Devane, Kenneth Iain Cumming, Maurice Joseph Anthony Clancy, Janet Elizabeth Codd, Gary G. Liversidge
-
Publication number: 20090275563Abstract: Patients suffering from serotonin-mediated diseases or conditions, such as depression, may be treated by administering an effective combined amount of a 5-HT7 receptor antagonist and a serotonin reuptake inhibitor.Type: ApplicationFiled: October 18, 2006Publication date: November 5, 2009Inventor: Pascal Bonaventure
-
Publication number: 20090258860Abstract: Methods and compositions are provided for treating vascular depression. The methods involve administering to a subject in need thereof a xanthine derivative in a therapeutically effective amount to treat vascular depression, particularly the xanthine derivatives pentoxifylline or propentofylline. The methods may further include administration of an additional therapeutic agent in combination with the xanthine derivative selected from the group consisting of a selective serotonin reuptake inhibitor (SSRI), a serotonin-norepinephrine reuptake inhibitor (SNRI), and a drug used in the treatment of cerebrovascular disease. Compositions of the invention include pharmaceutical compositions and kits for treating vascular depression in a subject in need thereof that include therapeutically effective amounts of a xanthine derivative and an additional therapeutic agent selected from the group consisting of an SSRI, an SNRI, and a drug used in the treatment of cerebrovascular disease.Type: ApplicationFiled: June 19, 2009Publication date: October 15, 2009Applicant: Duke UniversityInventor: Ranga Krishnan
-
Publication number: 20090258859Abstract: Cocrystals of metronidazole are described herein. Such cocrystals are a cocrystal of metronidazole with gentisic acid and a cocrystal of metronidazole with gallic acid. Cocrystals of imipramine hydrochloride are also described. Such cocrystals are a cocrystal of imipramine hydrochloride with (+)-camphoric acid, a cocrystal of imipramine hydrochloride with fumaric acid, and a cocrystal of imipramine hydrochloride with 1-hydroxy-2-naphthoic acid.Type: ApplicationFiled: December 8, 2006Publication date: October 15, 2009Applicant: SSCI, INC.Inventor: Scott Lawrence Childs
-
Publication number: 20090252793Abstract: Oral dosage forms comprising oxcarbazepine which when administered to a patient display no food effect.Type: ApplicationFiled: March 23, 2009Publication date: October 8, 2009Inventor: Steffen Lang
-
Publication number: 20090252704Abstract: The invention relates to a combination comprising an amount of an NO donor, such as ISDN, and/or an amount of another pharmaceutical agent that enhances neurotransmission or which acts as neuroprotectants such as memantine, clomethiazole and tacrine. These compositions can be used in producing cognition and learning enhancement, whereby the invention also provides for a new method of treatment of Alzheimer's disease and related neurodegenerative disorders.Type: ApplicationFiled: January 14, 2009Publication date: October 8, 2009Inventors: Allan M. GREEN, Robert Bender